Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2356 to 2370 of 9128 results

  1. Transverse tibial transport for diabetic foot ulceration

    Awaiting development Reference number: GID-HTG10873 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  2. Heart valve disease presenting in adults: investigation and management - transcatheter aortic valve implantation (TAVI) to treat aortic stenosis (update)

    In development Reference number: GID-NG10457 Expected publication date: TBC

    NICE guideline
    In development

  3. Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]

    In development Reference number: GID-TA11638 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]

    Awaiting development Reference number: GID-TA11978 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]

    In development Reference number: GID-TA11818 Expected publication date:  14 April 2027

    Technology appraisal guidance
    In development

  6. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    Awaiting development Reference number: GID-TA11782 Expected publication date:  29 April 2027

    Technology appraisal guidance
    Awaiting development

  7. Ex-situ machine perfusion devices to preserve deceased donor livers for transplantation

    In development Reference number: GID-HTG10874 Expected publication date:  20 August 2026

    HealthTech guidance
    In development

  8. Alectinib for treating unresectable locally advanced non-small-cell lung cancer [GID-TA12468]

    Awaiting development Reference number: GID-TA12468 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Technologies to improve detection of endometrial cancer

    Awaiting development Reference number: GID-HTG10173 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  10. Dostarlimab for untreated locally advanced rectal cancer with high microsatellite instability or mismatch repair deficiency [ID6747]

    Awaiting development Reference number: GID-TA11972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]

    In development Reference number: GID-TA11416 Expected publication date:  22 October 2026

    Technology appraisal guidance
    In development

  12. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development Reference number: GID-TA11096 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  13. Renal sympathetic denervation for resistant hypertension

    In development Reference number: GID-HTG10527 Expected publication date: TBC

    HealthTech guidance
    In development

  14. Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]

    Awaiting development Reference number: GID-TA11358 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]

    Awaiting development Reference number: GID-TA10993 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development